Journal Article

Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial

Vertefeuille, John F, Estivariz, Concepcion F, Wassilak, Steven G F, Kovacs, Stephanie D, Wilkinson, Amanda L, Hoque, Masuma, Lickness, Jacquelyn S, Anand, Abhijeet, Zhang, Yiting, Mainou, Bernardo A, Zaman, Khalequ, Pallansch, Mark A, Burns, Cara C, Konopka-Anstadt, Jennifer L, Oberste, M Steven, Coffee, Elizabeth, Abid, Talha, Snider, Cynthia J, An, Qian, Yunus, Mohammad

2023

Overview

Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine-derived poliovirus type 2 outbreaks. Bivalent oral poliovirus vaccine (bOPV; containing Sabin types 1 and 3) is the vaccine of choice for type 1 and type 3 outbreak responses. We aimed to assess immunological interference between nOPV2 and bOPV when administered concomitantly. We conducted an open-label, non-inferiority, randomised, controlled trial at two clinical trial sites in Dhaka, Bangladesh. Healthy infants aged 6 weeks were randomly assigned (1:1:1) using block randomisation, stratified by site, to receive nOPV2 only, nOPV2 plus bOPV, or bOPV only, at the ages of 6 weeks, 10 weeks, and 14 weeks. Eligibility criteria included singleton and full term (≥37 weeks’ gestation) birth and parents intending to remain in the study area for the duration of study follow-up activities. Poliovirus neutralising antibody titres were measured at the ages of 6 weeks, 10 weeks, 14 weeks, and 18 weeks. The primary outcome was cumulative immune response for all three poliovirus types at the age of 14 weeks (after two doses) and was assessed in the modified intention-to-treat population, which was restricted to participants with adequate blood specimens from all study visits. Safety was assessed in all participants who received at least one dose of study product. A non-inferiority margin of 10% was used to compare single and concomitant administration. This trial is registered with ClinicalTrials.gov, NCT04579510. Between Feb 8 and Sept 26, 2021, 736 participants (244 in the nOPV2 only group, 246 in the nOPV2 plus bOPV group, and 246 in the bOPV only group) were enrolled and included in the modified intention-to-treat analysis. After two doses, 209 (86%; 95% CI 81–90) participants in the nOPV2 only group and 159 (65%; 58–70) participants in the nOPV2 plus bOPV group had a type 2 poliovirus immune response; 227 (92%; 88–95) participants in the nOPV2 plus bOPV group and 229 (93%; 89–96) participants in the bOPV only group had a type 1 response; and 216 (88%; 83–91) participants in the nOPV2 plus bOPV group and 212 (86%; 81–90) participants in the bOPV only group had a type 3 response. Co-administration was non-inferior to single administration for types 1 and 3, but not for type 2. There were 15 serious adverse events (including three deaths, one in each group, all attributable to sudden infant death syndrome); none were attributed to vaccination. Co-administration of nOPV2 and bOPV interfered with immunogenicity for poliovirus type 2, but not for types 1 and 3. The blunted nOPV2 immunogenicity we observed would be a major drawback of using co-administration as a vaccination strategy. The US Centers for Disease Control and Prevention.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Antibodies / Antibodies, Viral / Bangladesh - epidemiology / Contraindications / Disease control / Epidemics / Humans / Immune response / Immune system / Immunization Schedule / Immunogenicity / Immunogenicity, Vaccine / Immunology / Infant / Infant mortality / Infants / Infectious diseases / Labels / Outbreaks / Poliomyelitis / Poliomyelitis - epidemiology / Poliovirus / Poliovirus Vaccine, Inactivated / Poliovirus Vaccine, Oral / Randomization / Review boards / Risk management / SIDS / Sudden infant death syndrome / Surveillance / Vaccines